# Yeztugo® (lenacapavir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lenacapavir

> The PDUFA target action date for Yeztugo® (lenacapavir), sponsored by GILEAD SCIENCES, INC. (GILD), is February 2, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Yeztugo® (lenacapavir) PDUFA date?

The PDUFA target action date for Yeztugo® (lenacapavir), sponsored by GILEAD SCIENCES, INC. (GILD), is February 2, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." Last confirmed October 30, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/lenacapavir)

Source: Press release filed with the SEC (EX-99), accession 0000882095-26-000028, https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm (retrieved 2026-11-12). Last confirmed 2026-10-30. Cite: https://sec-api.dev/pdufa/lenacapavir#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Yeztugo® (lenacapavir) |
| Codes | GS-6207 |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [HIV-1-infection](https://sec-api.dev/indications/hiv-1-infection), [Pre-Exposure Prophylaxis of HIV Infection](https://sec-api.dev/indications/pre-exposure-prophylaxis-of-hiv-infection), [HIV-1 Infection](https://sec-api.dev/indications/hiv-1-infection), [HIV Infections](https://sec-api.dev/indications/hiv-infections), [HIV Pre-exposure Prophylaxis](https://sec-api.dev/indications/hiv-pre-exposure-prophylaxis) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### February 28, 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22215973%2C215974Orig1s000OtherActionLtrs.pdf%22

### December 22, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Sunlenca | lenacapavir | 12/22/2022 | To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerationsPress Release (FDA Archive)Drug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA215974 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20221222, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22
- openFDA Drugs@FDA: "NDA215973 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20221222, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215973%22

### November 25, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215974 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241125, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22
- openFDA Drugs@FDA: "NDA215973 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20241125, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215973%22

### April 24, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-04-24, last confirmed 2025-04-24.
- Press release filed with the SEC (EX-99) (accession 0000882095-25-000009): "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm

### June 18, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA220020 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product YEZTUGO (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220020%22

### June 19, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-04-24, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0000882095-25-000009): "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm
- SEC Form 10-Q (accession 0000882095-25-000012): "•Announced U.S. Food and Drug Administration ("FDA") accepted New Drug Applications submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a Prescription Drug User Fee Act date of June 19, 2025." https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/gild-20250331.htm
- openFDA Drugs@FDA: "NDA220020 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product YEZTUGO (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220020%22

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-04-24, last confirmed 2025-04-24.
- Press release filed with the SEC (EX-99) (accession 0000882095-25-000009): "•Presented initial Phase 1 data evaluating investigational once-yearly lenacapavir for HIV prevention at the Conference on Retroviruses and Opportunistic Infections ("CROI"), and announced plans to launch a Phase 3 study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm

### September 29, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." https://clinicaltrials.gov/study/NCT05502341

### October 27, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." https://clinicaltrials.gov/study/NCT06333808

### May 28, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Pre-Exposure Prophylaxis of HIV Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06513312 (Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06513312

### July 22, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Pre-Exposure Prophylaxis of HIV Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06101329 (Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06101329

### July 27, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Pre-Exposure Prophylaxis of HIV Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06101342 (Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-27 (ACTUAL); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06101342

### August 4, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0000882095-26-000028): "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm

### August 27, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215974 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22
- openFDA Drugs@FDA: "NDA215973 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215973%22

### October 21, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." https://clinicaltrials.gov/study/NCT05502341?tab=results

### November 5, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." https://clinicaltrials.gov/study/NCT06333808?tab=results

### February 2, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-04, last confirmed 2026-10-30.
- Press release filed with the SEC (EX-99) (accession 0000882095-26-000028): "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm
- SEC Form 10-Q (accession 0000882095-26-000039): "•Announced FDA accepted a supplemental New Drug Application ("NDA") submission for Yeztugo 300-mg tablet as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis, with a Prescription Drug User Fee Act ("PDUFA") target action date of February 2, 2027." https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/gild-20260930.htm
- SEC Form 10-Q (accession 0000882095-26-000031): "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application ("NDA") submission for Yeztugo 300-mg tablet as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis, with a Prescription Drug User Fee Act ("PDUFA") target action date of February 2, 2027." https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07645287 (A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07645287

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07645287 (A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07645287

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: HIV-1 Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07841990 (Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07841990

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: HIV-1 Infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07841990 (Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07841990

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: HIV Pre-exposure Prophylaxis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07047716 (Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07047716

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: HIV Pre-exposure Prophylaxis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07047716 (Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07047716

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07682961 (Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07682961

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07682961 (Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07682961

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07683000 (Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07683000

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07683000 (Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07683000

### July 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06532656 (Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06532656

### Jul to Oct 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06532656 (Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06532656

### October 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07708727 (Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07708727

### Oct 2030 to Jan 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: HIV-1-infection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07708727 (Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT07708727

## Same indication

- [Cab la](https://sec-api.dev/pdufa/cab-la) (GSK)
- [Cab la + rpv la](https://sec-api.dev/pdufa/cab-la-rpv-la) (GSK)
- [Vocabria (cabotegravir sodium)](https://sec-api.dev/pdufa/cabotegravir) (GSK)
- [Dor/isl](https://sec-api.dev/pdufa/dor-isl) (MRK)
- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc) (GSK)
- [MK-8591A](https://sec-api.dev/pdufa/mk-8591a) (MRK)
- [Oral lenacapavir](https://sec-api.dev/pdufa/oral-lenacapavir) (GILD)
- [VH4524184](https://sec-api.dev/pdufa/vh4524184) (GSK)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lenacapavir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Yeztugo® (lenacapavir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lenacapavir

```bibtex
@misc{secapidev_pdufa_lenacapavir_20261116,
  title        = {Yeztugo® (lenacapavir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lenacapavir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lenacapavir_20261116","title":"Yeztugo® (lenacapavir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lenacapavir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
